Market Place
Sourcing Support
Panavance Announces Misetionamide Inhibits Oncogenic c-MYC
19 Nov 2024 //
GLOBENEWSWIRE
Panavance Updates On Misetionamide Trial At VMC 2024
09 Oct 2024 //
GLOBENEWSWIRE
Panavance Announces Misetionamide Publication In Cancer Medicine For Cancer
14 Aug 2024 //
GLOBENEWSWIRE
Anti-Cancer Drugs Publishes Data Demonstrating the Activity of GP-2250
01 Feb 2024 //
GLOBENEWSWIRE
International Journal of Molecular Sciences Publishes Data of GP-2250
21 Nov 2023 //
GLOBENEWSWIRE
Panavance to Present at the BIO Investor Forum
05 Oct 2023 //
GLOBENEWSWIRE
Journal of Cellular and Molecular Medicine Publishes Data of Panavance™s GP-2250
12 Sep 2023 //
GLOBENEWSWIRE
Panavance to Participate in the Virtual Investor Summer Spotlight Series
05 Jul 2023 //
GLOBENEWSWIRE
Panavance Announces Publication of Encouraging Preclinical Data GP-2250
29 Jun 2023 //
GLOBENEWSWIRE
Panavance Therapeutics to Present at (BIO) International Convention
24 May 2023 //
GLOBENEWSWIRE
Panavance Therapeutics Announces Positive Preclinical Data Demonstrating
17 Apr 2023 //
GLOBENEWSWIRE
Panavance Therapeutics to Present at the BioNJ Annual BioPartnering Conference
12 Apr 2023 //
GLOBENEWSWIRE
Panavance Announces Acceptance of Abstract to be Presented at AACR
20 Mar 2023 //
GLOBENEWSWIRE
Panavance Therapeutics to Present at the Virtual Investor 2023 to Watch Event
05 Jan 2023 //
GLOBENEWSWIRE
Panavance to Participate at the Virtual Investor Innovations in Oncology Event
05 Dec 2022 //
GLOBENEWSWIRE
Panavance Publishes Promising PC Data Evaluating GP-2250
08 Aug 2022 //
GLOBENEWSWIRE
Panavance Announces ODD for GP-2250 for the Treatment of Pancreatic Cancer
28 Jun 2022 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.